Clinical-stage biopharmaceutical company Arcus Biosciences Inc (NYSE:RCUS) announced on Wednesday that it has entered into a clinical trial collaboration and supply agreement with biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE:BMY) to evaluate casdatifan (AB521) in combination with a PD-L1/VEGF-A bispecific immunomodulator in advanced renal cell carcinoma.

The collaboration will support evaluation within the BMS-sponsored Phase 1/2 ROSETTA RCC-208 study of pumitamig (BNT327/BMS986545), an investigational PD-L1/VEGF-A bispecific antibody developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatment options.

Under the agreement, Arcus will supply casdatifan, an investigational HIF-2a inhibitor, which will be incorporated as two additional treatment arms in the ROSETTA RCC-208 trial. Each company will retain its respective development and commercial rights, and the arrangement is structured as mutually non-exclusive.

This collaboration aligns with Arcus's broader development strategy to evaluate casdatifan across multiple treatment settings in kidney cancer, including combinations and sequential regimens across different lines of therapy. Casdatifan remains investigational, with safety and efficacy not yet established and no regulatory approvals granted.